Diagnostic and Prognostic Value of Circulating DNA Fragments in Glioblastoma Multiforme Patients
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25084221 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Pawel Jarmuzek und 4 weiteren Autor:innen. Beteiligte Einrichtung: Neurosurgery Center University Hospital, Collegium Medicum University of Zielona Gora, 28 Zyty Str., 65-417 Zielona Gora, Poland. Hauptthemen laut MEDLINE: Glioblastoma, Biomarkers, Tumor, Cell-Free Nucleic Acids. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Zielona Gora.
Abstract (Originalsprache)
Novel blood-circulating molecules, as potential biomarkers for glioblastoma multiforme (GBM) diagnosis and monitoring, are attracting particular attention due to limitations of imaging modalities and invasive tissue biopsy procedures. This study aims to assess the diagnostic and prognostic values of circulating cell-free DNA (cfDNA) in relation to inflammatory status in GBM patients and to determine the concentration and average size of DNA fragments typical of tumour-derived DNA fractions. Preoperative plasma samples from 40 patients (GBM 65.0 ± 11.3 years) and 40 healthy controls (HC 70.4 ± 5.4 years) were compared. The cfDNA concentrations and lengths were measured using the electrophoresis platform, and inflammatory indices (NLR, PLR, LMR, and SII) were calculated from complete blood cell analysis. More fragmented cfDNA and 4-fold higher 50–700 bp cfDNA concentrations were detected in GBM patients than in healthy controls. The average cfDNA size in the GBM group was significantly longer (median 336 bp) than in the HC group (median 271 bp). Optimal threshold values were 1265 pg/μL for 50–700 bp cfDNA (AUC = 0.857) and 290 bp for average cfDNA size (AUC = 0.814). A Kaplan–Meier survival curves analysis also demonstrated a higher mortality risk in the GBM group with a cut-off >303 bp cfDNA. This study is the first to have revealed glioblastoma association with high levels of cfDNA > 1000 pg/μL of 50–700 bp in length, which can be aggravated by immunoinflammatory reactivity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurosurgery Center University Hospital, Collegium Medicum University of Zielona Gora, 28 Zyty Str., 65-417 Zielona Gora, Poland.
- Department of Applied and Clinical Physiology, Collegium Medicum University of Zielona Gora, 28 Zyty Str., 65-417 Zielona Gora, Poland.
ORCID-Profile: Pawel Jarmuzek, Edyta Wawrzyniak-Gramacka, Barbara Morawin, Agnieszka Zembron-Lacny
Förderung
- University of Zielona Gora
Zitieren
APA
Jarmuzek, P., Wawrzyniak-Gramacka, E., Morawin, B., Tylutka, A., & Zembron-Lacny, A. (2024). Diagnostic and Prognostic Value of Circulating DNA Fragments in Glioblastoma Multiforme Patients. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25084221
Vancouver
Jarmuzek P, Wawrzyniak-Gramacka E, Morawin B, Tylutka A, Zembron-Lacny A. Diagnostic and Prognostic Value of Circulating DNA Fragments in Glioblastoma Multiforme Patients. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25084221
BibTeX
@article{Jarmuzek2024,
author = {Jarmuzek, Pawel and Wawrzyniak-Gramacka, Edyta and Morawin, Barbara and Tylutka, Anna and Zembron-Lacny, Agnieszka},
title = {Diagnostic and Prognostic Value of Circulating DNA Fragments in Glioblastoma Multiforme Patients},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25084221}
}
EUVIMED